Show simple item record

dc.creatorAlape Girón, Alberto
dc.creatorMoreira Soto, Andrés
dc.creatorArguedas Gómez, Mauricio
dc.creatorBrenes Porras, Hebleen
dc.creatorBuján Boza, Willem Aart
dc.creatorCorrales Aguilar, Eugenia
dc.creatorDíaz Oreiro, Cecilia
dc.creatorEcheverri McCandless, Ann
dc.creatorFlores Díaz, Marietta
dc.creatorGómez Argüello, Aarón
dc.creatorHernández Bolaños, Andrés
dc.creatorHerrera Vega, María
dc.creatorLeón Montero, Guillermo
dc.creatorMacaya Hayes, Román
dc.creatorMolina Mora, José Arturo
dc.creatorMora Rodríguez, Javier Francisco
dc.creatorNarayanan, Aarthi
dc.creatorSanabria Castro, Alfredo
dc.creatorSánchez Brenes, Andrés
dc.creatorSánchez Céspedes, Laura Vanessa
dc.creatorSegura Ruiz, Álvaro
dc.creatorSegura Agüero, Eduardo
dc.creatorSolano Centeno, Daniela
dc.creatorSoto Garita, Claudio
dc.creatorStynoski, Jennifer Lynn
dc.creatorVargas Arroyo, Mariángela
dc.creatorVillalta Arrieta, Mauren
dc.creatorDrexler, Jan Felix
dc.creatorGutiérrez, José María
dc.date.accessioned2022-05-06T16:57:32Z
dc.date.available2022-05-06T16:57:32Z
dc.date.issued2021-09
dc.identifier.citationwww.frontiersin.org/articles/10.3389/fmed.2021.743325es_ES
dc.identifier.issn2296-858X
dc.identifier.urihttps://hdl.handle.net/10669/86549
dc.description.abstractThe emergence and dissemination of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting COVID-19 pandemic triggered a global public health crisis. Although several SARS-CoV-2 vaccines have been developed, demand far exceeds supply, access to them is inequitable, and thus, populations in low- and middle-income countries are unlikely to be protected soon (1). Furthermore, there are no specific therapies available, which is a challenge for COVID-19 patient care (2). Thus, the appearance of SARS-CoV-2 variants and reports of reinfections associated with immune escape (3, 4) highlight the urgent need for effective and broad coverage COVID-19 therapeutics. Intravenous administration of human or heterologous antibodies is a therapy successfully used in patients with viral respiratory diseases (5). Accordingly, formulations containing SARS-CoV-2 specific antibodies are an attractive therapeutic option for COVID-19 patients (6). SARS-CoV-2 specific antibodies could limit infection by direct virion neutralization and/or by targeting infected cells for elimination via complement or antibody-mediated cytotoxicity (6). Specific SARS-CoV-2 antibody-based therapeutics include convalescent plasma (CP), monoclonal antibodies (mAbs), human polyclonal IgG formulations purified from CP or transgenic animals, and heterologous hyperimmune polyclonal antibodies (pAbs) (6). Although the window for using antibody-based therapeutics varies, clinical data show that they are mainly effective if administered early after symptoms onset (6).es_ES
dc.description.sponsorshipUniversidad de Costa Rica/[741-C0-198]/UCR/Costa Ricaes_ES
dc.description.sponsorshipCaja Costarricense del Seguro Social/[]/CCSS/Costa Ricaes_ES
dc.description.sponsorshipBanco Centroamericano de Integración Económica/[]/BCIE/Costa Ricaes_ES
dc.description.sponsorshipGerman academic exchange services/[57592642]/DAAD/Alemaniaes_ES
dc.language.isoenges_ES
dc.sourceFrontiers in Medicine, vol.8, pp.1-5.es_ES
dc.subjectHeterologous antibodieses_ES
dc.subjectPassive immunotherapyes_ES
dc.subjectCOVID-19es_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectHyperimmune polyclonal antibodieses_ES
dc.subjectConvalescent plasmaes_ES
dc.subjectMonoclonal antibodieses_ES
dc.titleHeterologous hyperimmune polyclonal antibodies against SARS-COV-2: A broad coverage, affordable, and scalable potential immunotherapy for Covid-19es_ES
dc.typeartículo científicoes_ES
dc.identifier.doi10.3389/fmed.2021.743325
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP)es_ES
dc.description.procedenceUCR::Vicerrectoría de Docencia::Salud::Facultad de Medicina::Escuela de Medicinaes_ES
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Centro de Investigación en Enfermedades Tropicales (CIET)es_ES
dc.identifier.codproyecto741-C0-198


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record